Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by J&P Medical Research Ltd.
Sponsor:
Collaborators:
InfectoPharm Arzneimittel und Consilium GmbH
Sandoz GmbH
Information provided by (Responsible Party):
J&P Medical Research Ltd.
ClinicalTrials.gov Identifier:
NCT01173575
First received: July 29, 2010
Last updated: October 27, 2014
Last verified: October 2014

July 29, 2010
October 27, 2014
August 2010
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01173575 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection
Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection

This project aims to assess the clinical and microbiological efficacy of fosfomycin(FOM) in patients with bacterial infection.

Primary objective:

• To assess clinical and microbiological efficacy of FOM in patients with bacterial infection.

Secondary objectives:

  • To determine the rate and severity of unexpected adverse events.
  • To determine the mean duration of therapy with FOM in patients with bacterial infection.

Study design:

Multi-center, non-interventional study

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Any subject with bacterial infection considered suitable for routine antimicrobial therapy with FOM may be included into this analysis.

Bacterial Infection
Not Provided
Bacterial Infection
All Patients with bacterial infection receiving fosfomycin may be included
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Not Provided
Not Provided

Inclusion Criteria:

  • Patients with bacterial infection receiving FOM for clinical purposes will be included into the analysis.

Exclusion Criteria:

-

Both
Not Provided
No
Contact: Freyja Maria Jüttner-Smolle, Prof., MD +43/ 316 385 ext 3302 freyja.smolle@medunigraz.at
Austria,   Germany
 
NCT01173575
J&P009SAN/2009
No
J&P Medical Research Ltd.
J&P Medical Research Ltd.
  • InfectoPharm Arzneimittel und Consilium GmbH
  • Sandoz GmbH
Not Provided
J&P Medical Research Ltd.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP